Generation of CAR-T Cells for Cancer Immunotherapy
- 22 November 2018
- book chapter
- Published by Springer Nature
- Vol. 1884, 349-360
Abstract
T cells engineered with chimeric antigen receptors (CARs) are emerging as powerful cancer immunotherapies. Remarkable efficacies have been demonstrated in treating B-cell malignancies with CAR-T cells, leading to the FDA’s first approval of gene therapy. Currently, numerous clinical trials for hematological malignancies and solid tumors are underway worldwide. Production of CAR-T cells with proper qualities is essential for CAR-T success in vivo. Here we detail optimized protocols for the generation of CAR-T cells for preclinical studies using lentiviral gene transfer, expansion of CAR-T cells in culture, detection of CAR expression, and evaluation of CAR-T cellular cytotoxicity in vitro.Keywords
This publication has 25 references indexed in Scilit:
- Chimeric Antigen Receptor (CAR)-Specific Monoclonal Antibody to Detect CD19-Specific T Cells in Clinical TrialsPLOS ONE, 2013
- Sleeping Beauty System to Redirect T-cell Specificity for Human ApplicationsJournal of Immunotherapy, 2013
- Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T CellsFrontiers in Immunology, 2013
- Protein L: a novel reagent for the detection of Chimeric Antigen Receptor (CAR) expression by flow cytometryJournal of Translational Medicine, 2012
- T Cell Receptor (TCR) Gene Transfer with Lentiviral Vectors Allows Efficient Redirection of Tumor Specificity in Naive and Memory T Cells Without Prior Stimulation of Endogenous TCRHuman Gene Therapy, 2009
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen ReceptorJournal of Immunotherapy, 2009
- Selecting highly affine and well-expressed TCRs for gene therapy of melanomaBlood, 2007
- The ABCs of artificial antigen presentationNature Biotechnology, 2004
- Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competenceBlood, 2003
- The cytoplasmic domain of the T cell receptor ζ chain is sufficient to couple to receptor-associated signal transduction pathwaysCell, 1991